Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review ...

Summary by targetedonc.com
FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

targetedonc.comtargetedonc.com

FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies

FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.

Read Full Article
Business WireBusiness Wire

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review ...

·Crystal River, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Business Wire broke the news in Crystal River, United States on Thursday, July 24, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

You have read 1 out of your 5 free daily articles.

News
For You
SearchBlindspotLocal